This finding is confirmed by results from a Japanese study with gefitinib in which an age < 75 years was an independent negative factor affecting PFS after EGFR-TKI therapy in patients with advanced NSCLC [53]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.